Asset profile
MB310
Microbiome therapeutic
Evidence outlook · lead readout
NCT06582264 · Ulcerative Colitis
The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.
NCT06582264: This trial randomly assigned patients to MB310 or a matching placebo under blinded conditions, which supports a fair comparison, but it enrolled only 29 patients and its main measure was safety rather than the disease-related outcomes it also tracked as secondary measures. With no results posted yet, there is no read on how MB310 performed.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.